Health and Fitness Health and Fitness
Fri, September 3, 2010
[ Fri, Sep 03rd 2010 ] - Market Wire
Herbert A. Fritsche, Ph.D., cientista e antigo pr .. o do Anderson Cancer Center, junta-se a Health Di
[ Fri, Sep 03rd 2010 ] - Market Wire
American Learning Corporation to Appeal Nasdaq Delisting Notice
[ Fri, Sep 03rd 2010 ] - Market Wire
KCI?????LifeCella" ???Novadaq Technologies????????????SPY®????????????
[ Fri, Sep 03rd 2010 ] - Market Wire
/C O R R E C T I O N - Mindray Medical International Limited /
[ Fri, Sep 03rd 2010 ] - Market Wire
MDS to Release Third Quarter 2010 Financial Results
[ Fri, Sep 03rd 2010 ] - Market Wire
Tibotec Pharmaceuticals Seeks European Marketing .. r Investigational Once-Daily HIV Treatment TMC278
[ Fri, Sep 03rd 2010 ] - Market Wire
Medisafe 1 Technologies Clarifies the PR Issued o .. ividend, as a Forward Split of 5-1 in the Form of
[ Fri, Sep 03rd 2010 ] - Market Wire
Gilead Sciences dient aanvraag in voor Europese m .. van ©©n tablet per dag van Truvada en TMC278 t
[ Fri, Sep 03rd 2010 ] - Market Wire
Alcon Launches AcrySof® IQ ReSTOR® Toric Intraocular Lens Outside the United States
[ Fri, Sep 03rd 2010 ] - Market Wire
Gilead Sciences Submits European Marketing Applic .. blet Regimen of Truvada® and TMC278 for the Trea
Thu, September 2, 2010
[ Thu, Sep 02nd 2010 ] - Market Wire
Law Offices of Howard G. Smith Announces Investigation on Behalf of Shareholders of Allergan, Inc.
[ Thu, Sep 02nd 2010 ] - Market Wire
Derma Sciences Novel XTRASORB® HCS Dressings Rec .. des; Join Foam and Classic Dressings for Complete
[ Thu, Sep 02nd 2010 ] - Market Wire
BioDelivery Sciences Announces Positive Meeting w .. eamlined ONSOLIS REMS with Broadened Distribution
[ Thu, Sep 02nd 2010 ] - Market Wire
BRINAVESSa" (vernakalant) goedgekeurd voor infusi .. elle conversie van recent ontstaan atriumfibrille
[ Thu, Sep 02nd 2010 ] - Market Wire
Obagi Medical Products Gives Notice of Terminatio .. Agreement With Dr. Zein Obagi and Related Parties
[ Thu, Sep 02nd 2010 ] - Market Wire
Herbert A. Fritsche, Ph.D., voormalig hoogleraar .. Anderson Cancer Center, wordt senior vice-presid
[ Thu, Sep 02nd 2010 ] - Market Wire
BRINAVESSa" (vernakalant) en perfusion a reu l'ap .. ne pour la conversion rapide de la fibrillation a
[ Thu, Sep 02nd 2010 ] - Market Wire
BRINAVESSa" (vernakalant) per infusione approvato .. conversione rapida della fibrillazione atriale di
[ Thu, Sep 02nd 2010 ] - Market Wire
LifeCella" Corporation de KCI y Novadaq Technolog .. ntas y comercializacin en Am©rica del Norte para
[ Thu, Sep 02nd 2010 ] - Market Wire
KCIa?s LifeCell Corporation en Novadaq Technologi .. verkoop- en marketingovereenkomst voor exclusieve
[ Thu, Sep 02nd 2010 ] - Market Wire
HealthSpring, Inc. to Present at the Stifel Nicolaus Healthcare Conference
[ Thu, Sep 02nd 2010 ] - Market Wire
American HomePatient Announces Successful Results of Self-Tender Offer and Debt Restructuring
[ Thu, Sep 02nd 2010 ] - Market Wire
Seattle Genetics Achieves Milestone under Antibod .. laboration with Agensys, an Affiliate of Astellas
[ Thu, Sep 02nd 2010 ] - Market Wire
Humana Names Stephen Macias Specialty Market President in Northern California
[ Thu, Sep 02nd 2010 ] - Market Wire
Cardiome Achieves $30 Million Milestone
[ Thu, Sep 02nd 2010 ] - Market Wire
Oncolytics Biotech(R) Inc. Announces Randomized P .. to be Conducted by the Gynecologic Oncology Group
[ Thu, Sep 02nd 2010 ] - Market Wire
NUVO RESEARCH TO PRESENT AT RODMAN &; RENSHAW 12TH ANNUAL HEALTHCARE CONFERENCE
[ Thu, Sep 02nd 2010 ] - Market Wire
Gilead geeft update over aandelenterugkoop van 5 miljard dollar
[ Thu, Sep 02nd 2010 ] - Market Wire
AVEO Pharmaceuticals, Inc. to Present at Several Upcoming Investment Conferences
[ Thu, Sep 02nd 2010 ] - Market Wire
ImmunoGen, Inc. Announces Webcast of Presentations at Multiple Investor Conferences in September

ImmunoGen, Inc. Announces Webcast of Presentations at Multiple Investor Conferences in September


Published on 2010-09-02 06:36:20 - Market Wire
  Print publication without navigation


WALTHAM, Mass.--([ BUSINESS WIRE ])--[ ImmunoGen, Inc ]. (Nasdaq: IMGN), a biotechnology company that develops antibody-based targeted anticancer products, today announced that Company management will present at multiple investor conferences this month. The live webcast of each presentation can be accessed through the aInvestor Informationa section of the Companya™s website, [ www.immunogen.com ]; a replay of each presentation will be available for one week.

  • 2010 Morgan Stanley Global Healthcare Unplugged Conference
    8:00 a.m.EDT on September 13, 2010in New York, NY
    Presenter: Daniel Junius, President and CEO
  • Stifel Nicolaus 2010 Healthcare Conference
    11:30 a.m.EDT on September 15, 2010in Boston, MA
    Presenter: Gregory Perry, Senior Vice President and CFO
  • Bank of America Merrill Lynch Global Healthcare Conference 2010
    1:00 p.m.BST (8:00 a.m. EDT) on September 16, 2010in London,England
    Presenter: Daniel Junius, President and CEO
  • UBS Global Life Sciences Conference
    12:00 p.m.EDT on September 20, 2010inNew York, NY
    Presenter: Gregory Perry, Senior Vice President and CFO

About ImmunoGen, Inc.

ImmunoGen, Inc. develops targeted anticancer therapeutics using its expertise in cancer biology, monoclonal antibodies and the creation and attachment of potent cancer cell-killing agents. The Companya™s Targeted Antibody Payload (TAP) technology uses engineered antibodies to deliver one of ImmunoGena™s proprietary cancer-cell killing agents specifically to tumor targets. Product candidates are in development through the Companya™s own product programs and through ImmunoGena™s collaborations with Amgen, Bayer Schering Pharma, Biogen Idec, Biotest, Genentech (a member of the Roche Group), and sanofi-aventis. The most advanced compound using ImmunoGena™s TAP technology, T-DM1, is in Phase III testing through the Companya™s collaboration with Genentech.

Contributing Sources